Moberg Pharma is forecast to grow earnings and revenue by 100.9% and 63.3% per annum respectively while EPS is expected to grow by 100.9% per annum.
Key information
100.9%
Earnings growth rate
100.90%
EPS growth rate
Pharmaceuticals earnings growth
14.6%
Revenue growth rate
63.3%
Future return on equity
n/a
Analyst coverage
Low
Last updated
13 May 2026
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
OTCPK:MBGP.F - Analysts future estimates and past financials data (SEK Millions)
Date
Revenue
Earnings
Free Cash Flow
Cash from Op
Avg. No. Analysts
12/31/2028
95
27
N/A
34
1
12/31/2027
56
9
N/A
15
1
12/31/2026
23
-18
N/A
-16
1
3/31/2026
15
-26
-45
-12
N/A
12/31/2025
14
-27
-61
-17
N/A
9/30/2025
12
-258
-71
-16
N/A
6/30/2025
12
-255
-80
-14
N/A
3/31/2025
13
-251
-92
-21
N/A
12/31/2024
10
-255
-90
-16
N/A
9/30/2024
9
-18
-115
-27
N/A
6/30/2024
5
-23
-134
-33
N/A
3/31/2024
1
-23
-139
-31
N/A
12/31/2023
N/A
-21
-157
-33
N/A
9/30/2023
N/A
-18
-134
-29
N/A
6/30/2023
0
-16
-105
-21
N/A
3/31/2023
0
-16
-96
-16
N/A
12/31/2022
0
-16
-85
-17
N/A
9/30/2022
0
-17
-75
-14
N/A
6/30/2022
N/A
-16
-70
-12
N/A
3/31/2022
N/A
-16
-56
-7
N/A
12/31/2021
N/A
-16
-47
-15
N/A
9/30/2021
34
8
-44
-9
N/A
6/30/2021
34
7
-46
-12
N/A
3/31/2021
34
5
-58
-16
N/A
12/31/2020
34
7
-52
-10
N/A
6/30/2020
50
20
-47
4
N/A
6/30/2019
31
-8
N/A
-76
N/A
3/31/2019
455
31
N/A
88
N/A
12/31/2018
5
-28
N/A
74
N/A
9/30/2018
341
9
N/A
87
N/A
6/30/2018
340
19
N/A
109
N/A
3/31/2018
334
6
N/A
68
N/A
12/31/2017
439
11
N/A
54
N/A
9/30/2017
438
-1
N/A
30
N/A
6/30/2017
434
0
N/A
-44
N/A
3/31/2017
369
35
N/A
-17
N/A
12/31/2016
334
33
N/A
-18
N/A
9/30/2016
299
36
N/A
-21
N/A
6/30/2016
261
32
N/A
12
N/A
3/31/2016
282
9
N/A
32
N/A
12/31/2015
286
26
N/A
31
N/A
9/30/2015
276
25
N/A
34
N/A
6/30/2015
260
20
N/A
30
N/A
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBGP.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3.5%).
Earnings vs Market: MBGP.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MBGP.F is expected to become profitable in the next 3 years.
Revenue vs Market: MBGP.F's revenue (63.3% per year) is forecast to grow faster than the US market (12.1% per year).
High Growth Revenue: MBGP.F's revenue (63.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBGP.F's Return on Equity is forecast to be high in 3 years time
Discover growth companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/04 22:03
End of Day Share Price
2026/06/02 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Moberg Pharma AB (publ) is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.